GlaxoSmithKline PLC (GSK)
38.47USD
9 Feb 2010
$0.35 (+0.92%)
$38.47
--
$38.75
$37.95
3,263,009
2,316,888
$43.47
$27.15
GSK
About
Overall
| Beta: | 0.60 |
| Market Cap (Mil.): | $99,854.70 |
| Shares Outstanding (Mil.): | 2,595.65 |
| Annual Dividend: | 2.30 |
| Yield (%): | 5.97 |
Financials
| GSK | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 11.38 | 6.43 | 3.76 |
| EPS (TTM): | 24.56 | -- | -- |
| ROI: | 19.22 | 5.95 | 2.30 |
| ROE: | 61.67 | 8.98 | 2.82 |
UPDATE 2-Sanofi says vaccines to help lift 2010 earnings
* Q4 adj net income 1.8 bln euros vs Reuters poll 1.68 bln
UK Stocks -- Factors to watch on Feb 10
LONDON, Feb 10 (Reuters) - Britain's FTSE 100 is seen opening 19-23 points higher on Wednesday, after gains on Wall Street and in Asia with investor confidence buoyed by hopes Europe is close to bailing out debt-laden Greece.
UK court rules HGS gene patent invalid -lawyers
* Ruling upholds earlier decision that HGS patent is invalid
BlackRock targets overseas earnings for UK income
LONDON (Reuters) - BlackRock's UK income fund is targeting companies that derive most of their revenues from overseas as it sees stronger growth outside the UK, and has added to its holdings in energy and miners in pursuit of capital growth.
European shares briefly turn positive; miners gain
LONDON, Feb 9 (Reuters) - European shares briefly turned positive in early trading on Tuesday as stronger metals prices supported mining stocks and pharmaceutical shares gained ground.
Popular antidepressant interferes with cancer drug
WASHINGTON (Reuters) - The popular antidepressant drug Paxil may interfere with breast cancer treatments, making patients more likely to relapse and die, researchers in Canada reported on Monday.
Popular antidepressant interferes with cancer drug
WASHINGTON, Feb 8 (Reuters) - The popular antidepressant drug Paxil may interfere with breast cancer treatments, making patients more likely to relapse and die, researchers in Canada reported on Monday.
Miners, defensive rally helps FTSE up
LONDON (Reuters) - The top share index closed 0.6 percent higher on Monday, as gains in rebounding miners and strength in defensive issues more than offset weaker financials, which were weighed by ongoing eurozone debt issues.
Europe shares snap losing streak, defensives up
LONDON, Feb 8 (Reuters) - European shares snapped a three-day losing streak on Monday, boosted by defensive stocks such as drugmakers and commodities tracking crude and metal prices higher.
Competitors
| Price | Change | |
|---|---|---|
| Abbott Laboratories (ABT.N) | $53.35 | 0.00 |
| Amgen, Inc. (AMGN.OQ) | $57.21 | -0.25 |
| AstraZeneca plc (AZN.L) | £2,822.00 | +6.50 |
| Bristol Myers Squibb Co. (BMY.N) | $24.25 | +0.29 |
| Bristol Myers Squibb Co. (BMY_p.N) | $439.50 | 0.00 |
| Eli Lilly & Co. (LLY.N) | $35.20 | +0.42 |
| Johnson & Johnson (JNJ.N) | $62.76 | +0.39 |
| Merck & Co., Inc. (MRK.N) | $36.47 | -0.12 |
| Novartis AG (NOVN.VX) | CHF57.05 | +0.25 |
| Pfizer Inc. (PFE.N) | $17.88 | +0.04 |
Earnings vs 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
